“Novel chemical compounds with anti-malarial activity represent a potent tool in the process of developing new drugs to treat this disease,” Dr. Phillips said.
The study, done in collaboration with Dr. Kiplin Guy of St. Jude Children’s Research Hospital in Memphis and other researchers, started with a “library” of 309,474 chemical compounds.
The researchers used a technique called high throughput screening, which allowed them to test thousands of compounds quickly to identify those with anti-malarial action.
“In addition, publishing the full set of identified compounds will maximize the chances for the most-promising candidates to move into large-scale drug development programs,” Dr. Phillips said.
The screen identified 1,152 compounds that killed the parasite. The researchers then followed up with further tests to determine the mechanism of action of the identified compounds, where possible.
Dr. Phillips and her group tested whether any of the identified compounds killed malaria parasites by inhibiting an enzyme necessary to make pyrimidine, an intermediate molecule for creating DNA. She discovered that three of the library’s compounds with anti-malarial activity blocked this enzyme. Two of those had similar chemical structures to a class of known compounds that she and her colleagues have been studying for possible drug development. The third compound previously was not known to target the enzyme.
“It looked very different from anything we knew about before,” she said.
Having a variety of anti-malarial drugs with different chemical structures and modes of action is important because different types of drugs are given together to slow the parasite from developing resistance, Dr. Phillips said.
In all, the researchers from the various centers found 172 compounds that are “reasonable starting points” for development of new types of drugs.
“We call the identified candidates ‘hits,’ but if any of them are going to become drugs, they’re going to have to undergo chemical modification,” Dr. Phillips said. “For instance, they may need to be altered chemically to enter the cell more easily, or to improve their pharmacology so they will be more effective in people.”
Farah El Mazouni, senior research associate in pharmacology at UT Southwestern, also participated in this study. In addition, the researchers used the UT Southwestern High Throughput System resource in the Department of Biochemistry.
Other participating researchers were from St. Jude Children’s Research Hospital; Griffith University in Australia; the University of Washington, Seattle; the University of Pennsylvania; GlaxoSmithKline; the University of California, San Francisco; Johns Hopkins Bloomberg School of Public Health; the University of Pittsburgh; Medicines for Malaria Venture, Switzerland; the Portland VA Medical Center; and Rutgers, The State University of New Jersey.
The study was funded by the National Institutes of Health, the Welch Foundation, the Medicines for Malaria Venture and other organizations.Media Contact: Aline McKenzie
Aline McKenzie | EurekAlert!
Bolstering fat cells offers potential new leukemia treatment
17.10.2017 | McMaster University
Ocean atmosphere rife with microbes
17.10.2017 | King Abdullah University of Science & Technology (KAUST)
University of Maryland researchers contribute to historic detection of gravitational waves and light created by event
On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...
Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.
Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....
Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).
When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...
Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.
How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...
Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.
It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...
17.10.2017 | Event News
10.10.2017 | Event News
10.10.2017 | Event News
17.10.2017 | Life Sciences
17.10.2017 | Life Sciences
17.10.2017 | Earth Sciences